Australia's Therapeutic Goods Administration (TGA) has approved Skyhawk Therapeutics' clinical trial application for SKY-0515, enabling enrollment of Australian patients in the FALCON-HD Phase 2/3 trial for Huntington's Disease.
PRESS RELEASE
Australia's Therapeutic Goods Administration Approves SKY-0515 Clinical Trial
The TGA has approved the clinical trial application for SKY-0515 in Australia, supporting the global FALCON-HD Phase 2/3 trial expansion.